根据名称进行药物检索

Apo-Cyclosporine Oral 与 Lovastatin Extended-Release Tablets

Apo-Cyclosporine Oral 与 Lovastatin Extended-Release Tablets互相作用以及同时服用的可能性。

检测结果:

Apo-Cyclosporine Oral <> Lovastatin Extended-Release Tablets

现实性: 21.04.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用洛伐他一起药一般不建议。结合这些药物可以大大增加，血液水平的洛伐他. 这可能增加风险的副作用，例如肝脏损坏和一个罕见的，但严重的情况称为横纹肌瘤，涉及到崩溃的骨骼肌肉组织。在某些情况下，横纹肌瘤可造成肾脏损伤甚至死亡。谈谈你的医生如果你有任何疑问或关切的问题。你的医生可以规定替代品，不进行互动，或者可能需要一剂量的调整或更频繁的监测安全地使用这两种药物。让你的医生立即知道如果你有无法解释的肌肉疼痛、温柔、或弱点在处理与洛伐他或类似的药物，尤其是如果这些症状是伴随着发烧或暗色的尿液。你也应该立即寻求医疗照顾，如果你开发的热、冷、关节疼痛或肿胀、不寻常或出血瘀伤、皮疹、瘙痒，食欲不振、疲劳、恶心、呕吐、暗色的尿液和/或黄皮肤或眼睛，因为这些可能的迹象和症状的肝脏损伤。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予与药可能会显着增加的等离子浓度的洛伐他及其活动的β羟基酸代谢物，洛伐他酸。拟议的机构是药抑制的肠和肝CYP450 3A4，同工酶负责的新陈代谢的清洛伐他和洛伐他酸。此外，洛伐他酸是一种基材的肝脏吸收转运、有机的阴离子运输的多肽蛋白质(OATP)1B1和1B3，这也是抑制的环孢菌素。当洛伐他(10毫克每天一次为期10天)给予16孢菌素治疗的患者中，有5至8倍增加在洛伐他的系统暴露(AUC)相比，洛伐他单独给予. 高级别的英国政府CoA还原酶抑制活动等离子增加相关风险的骨骼肌肉毒性。肌病表现为肌肉疼痛和/或弱点相关的严重升高的肌酸激酶超过十倍正常上限已经报道的偶尔。横纹肌瘤也已发生很少，这可能是伴随着急性肾功能衰竭次要myoglobinuria，并可能导致死亡。已经有众多的情况报告的骨骼肌肉毒性相关联的使用孢菌素和英国政府CoA还原酶抑制剂，包括洛伐他和红酵母菌水稻。

管理：伴随使用的洛伐他或红曲米(其中包含洛伐他)与药一般应当是可以避免的。一些当局认为这种结合的禁忌。氟伐或普可能是合适的替代办法，虽然较低剂量的汀建议在结合环孢菌素。的产品的标签用于氟伐建议，氟伐量不超过20毫克每天两次当给与环孢菌素。的产品的标签用于普建议开始普至10毫克/天和不超过20毫克/天时给予与环孢菌素。在一般情况下，使用汀与环孢霉素应加以仔细权衡潜在的风险。所有患者接受汀治疗应立即报告任何无法解释的肌肉疼痛、温柔弱，尤其是如果伴随着发烧、萎靡不振，和/或暗色的尿液。治疗应该停止，如果肌酸磷酸激酶是明显升高，在没有剧烈的运动或者如果肌病是无怀疑或诊断。

来源

Southworth MR, Mauro VF "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients." Ann Pharmacother 31 (1997): 489-91
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.
Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988): 46-7
Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA "Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin." Am J Cardiol 84 (1999): 811-5
Arnadottir M, Eriksson LO, Germershausen JI, Thysell H "Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients." Nephron 68 (1994): 57-62
"Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb, Princeton, NJ.
Prasad GV, Wong T, Meliton G, Bhaloo S "Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient." Transplantation 74 (2002): 1200-1
Najafian B, Franklin DB, Fogo AB "Acute renal failure and myalgia in a transplant patient." J Am Soc Nephrol 18 (2007): 2870-4
Jardine A, Holdaas H "Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience." J Clin Pharm Ther 24 (1999): 397-408
Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A "Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine." Transplant Proc 31 (1999): 2522-3
Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW "Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions." Am J Med Sci 320 (2000): 394-7
Vanhaecke J, Vancleemput J, Vanlierde J, Daenen W, Degeest H "Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine." Transplantation 58 (1994): 42-5
Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S "Interaction between lovastatin and cyclosporine A after heart and kidney transplantation." Transplant Proc 31 (1999): 2163-5
Campana C, Iacona I, Regassi MB, et al. "Efficacy and pharmacokinetics of simvastatin in heart transplant recipients." Ann Pharmacother 29 (1995): 235-9
Cerner Multum, Inc. "Australian Product Information." O 0
Paoletti R, Corsini A, Bellosta S "Pharmacological interactions of statins." Atheroscler Suppl 3 (2002): 35-40
Francis L, Bonilla E, Soforo E, et al. "Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin." Clin Rheumatol 27 (2008): 129-31
Arnadottir M, Eriksson LO, Thysell H, Karkas JD "Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin." Nephron 65 (1993): 410-3
Rifkin SI "Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report." Medscape J Med 10 (2008): 264
Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74
"Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.
Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988): 239-41
Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
Maltz HC, Balog DL, Cheigh JS "Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine." Ann Pharmacother 33 (1999): 1176-9
East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8
Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V "Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients." Am J Nephrol 19 (1999): 411-5
"Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals, East Hanover, NJ.
Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7
"Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.